

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MICRO LABS LIMITED AND MICRO LABS USA INC.,  
Petitioner,

v.

SANTEN PHARMACEUTICAL CO., LTD. AND  
ASAHI GLASS CO., LTD.,  
Patent Owner.

---

Case IPR2017-01434  
U.S. Patent No. 5,886,035

---

**PATENT OWNER RESPONSE**

**TABLE OF CONTENTS**

TABLE OF AUTHORITIES ..... iii

LIST OF EXHIBITS .....iv

I. INTRODUCTION ..... 1

II. BACKGROUND ..... 7

    A. State of the Art as of the Priority Date  
        of the '035 Patent, December 26, 1996 ..... 7

    B. The '035 Patent ..... 15

    C. Prosecution History of the '035 Patent ..... 23

III. LEVEL OF ORDINARY SKILL IN THE ART ..... 23

IV. CLAIM CONSTRUCTION ..... 25

V. CLAIMS 1-14 OF THE '035 PATENT WOULD  
NOT HAVE BEEN OBVIOUS AS OF DECEMBER 26, 1996 ..... 25

    A. Legal Standard Regarding Obviousness  
        Based on Identification of an Alleged Lead Compound ..... 26

    B. A POSITA Would Not Have Considered  
        Compound C of Klimko To Be a Suitable Lead Compound ..... 28

        1. Klimko Expressly Teaches Away  
            from Compound C as a Lead Compound ..... 28

        2. Klimko Does Not Disclose Longer-Lasting  
            IOP-Lowering Efficacy by Compound C ..... 41

        3. Klimko Does Not Disclose Superior IOP-Lowering Efficacy  
            by Compound C at Sixteen Hours After the Fourth Dose ..... 44

        4. A POSITA Would Not Have Selected Klimko's  
            Compound C as a Lead Compound Based on Kishi ..... 45

        5. Petitioner's Identification of Compound C as a  
            Lead Compound Was Improperly Based on Hindsight ..... 46

C.	Prior Testimony by Petitioner's Main Expert, Dr. deLong, Directly Contradicts His Opinions in this Proceeding .....	47
D.	It Would Not Have Been Obvious to Modify Compound C of Klimko by C15 Fluorination .....	51
1.	A POSITA Would Not Have Been Motivated with a Reasonable Expectation of Success to Apply the Kishi Modification to Compound C of Klimko .....	51
2.	A POSITA Would Not Have Been Motivated with a Reasonable Expectation of Success to Modify Compound C of Klimko Using both the Kishi Modification and C15 Fluorination.....	53
E.	It Would Not Have Been Obvious to Difluorinate Compound C of Klimko .....	57
1.	Ueno Japan Is Irrelevant to IOP Lowering and Does Not Teach Any Particular Benefit of C15 Difluorination .....	57
2.	A POSITA Would Have Considered C15 Difluorination To Be a Radical Departure from Compound C of Klimko.....	61
F.	Klimko Specifically Excluded C15 Difluorinated Compounds from the Scope of Its Work.....	63
G.	Secondary Considerations .....	65
1.	Commercial Success/Copying .....	65
2.	Unexpected Results.....	66
3.	Long-Felt but Unmet Need .....	67
4.	Failure of Others .....	69
VI.	CONCLUSION.....	70
	CLAIM LISTING APPENDIX .....	71
	CERTIFICATE OF COMPLIANCE.....	74
	CERTIFICATE OF SERVICE .....	75

## TABLE OF AUTHORITIES

### Cases

<i>Eli Lilly and Co. v. Zenith Goldline Pharms., Inc.</i> , 471 F.3d 1369 (Fed. Cir. 2006) .....	49
<i>Otsuka Pharm. Co. v. Sandoz, Inc.</i> , 678 F.3d 1280 (Fed. Cir. 2012) .....	27, 28, 30
<i>Pfizer Inc. v. Teva Pharm. USA, Inc.</i> , 555 F. App'x 961 (Fed. Cir. 2014) .....	26, 27, 46
<i>PPC Broadband, Inc. v. Corning Optical Commc'ns RF LLC</i> , 815 F.3d 734 (Fed. Cir. 2016).....	66
<i>Takeda Chem. Indus., Ltd. v. Alphapharm Pty., Ltd.</i> , 492 F.3d 1350 (Fed. Cir. 2007) .....	27, 28, 29, 47

## LIST OF EXHIBITS

Exhibit No.	Document
2001	Declaration of Timothy L. Macdonald, Ph.D.
2002	Declaration of Robert D. Fechtner, M.D.
2003	Camras <i>et al.</i> , "Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits," <i>Invest. Ophthalmol. Vis. Sci.</i> 16:1125-1134 (1977)
2004	"Pharmacia Cleared To Market Xalatan, Drug for Glaucoma," <i>Wall St. J.</i> B7 (June 7, 1996)
2005	Fung and Whitson, "An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy," <i>Clin. Ophthalmol.</i> 8:543-554 (2014)
2006	Linden and Alm, "Prostaglandin Analogues in the Treatment of Glaucoma," <i>Drug Aging</i> , 14(5):387-398 (1999)
2007	Coleman <i>et al.</i> , "VIII. International Union of Pharmacology Classification of Prostanoid Receptors: Properties, Distribution, and Structure of the Receptors and Their Subtypes," <i>Pharmacol. Rev.</i> 46(2):205-229 (1994)
2008	Konturek and Pawlik, "Physiology and pharmacology of prostaglandins," <i>Dig. Dis. Sci.</i> 31(2 Suppl):6S-19S (1986)
2009	Stjernschantz and Alm, "Latanoprost as a new horizon in the medical management of glaucoma," <i>Curr. Opin. Ophthalmol.</i> 7(2):11-17 (1996)
2010	Collins and Djuric, "Synthesis of Therapeutically Useful Prostaglandin and Prostacyclin Analogs," <i>Chem. Rev.</i> 93:1533-1564 (1993)
2011	Giuffrè, "The effects of prostaglandin F <sub>2α</sub> in the human eye," <i>Graefe's Arch. Clin. Exp. Ophthalmol.</i> 222:139-141 (1985)
2012	Bito and Baroody, "The ocular pharmacokinetics of eicosanoids and their derivatives: 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF <sub>2α</sub> , PGF <sub>2α</sub> -1-methyl ester, and PGF <sub>2α</sub> -1-isopropyl ester," <i>Exp. Eye Res.</i> 44:217-26 (1987)
2013	Villumsen and Alm, "Prostaglandin F <sub>2α</sub> -isopropylester eye drops: effects in normal human eyes," <i>Br. J. Ophthalmol.</i> 73:419-26 (1989)
2014	Villumsen and Alm, "Ocular effects of two different prostaglandin F <sub>2α</sub> esters: a doublemasked cross-over study on normotensive eyes," <i>Acta Ophthalmol.</i> 68:341-343 (1990)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.